Nucresiran vs Patisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Nucresiran
Developed by Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07223203 (registry estimate)
No aligned efficacy figure on record for this race.
Patisiran · ONPATTRO
Marketed by Alnylam Pharmaceuticals
NCT01960348 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001).
Reported efficacy
Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) (met)
Result source: NCT01960348
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nucresiran's landscape · Patisiran's landscape